These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2409349)

  • 1. Pregnancy-associated plasma protein A and extensive necrosis. Clinically significant predictors of early recurrence in stage I estrogen receptor-negative breast carcinoma.
    Kuhajda FP; Eggleston JC
    Lab Invest; 1985 Jul; 53(1):101-7. PubMed ID: 2409349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy-associated plasma protein A. A clinically significant predictor of early recurrence in stage I breast carcinoma is independent of estrogen receptor status.
    Kuhajda FP; Eggleston JC
    Am J Pathol; 1985 Nov; 121(2):342-8. PubMed ID: 2414998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
    Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
    Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy-associated plasma protein A: a clinically significant predictor of early recurrence in stage II breast carcinoma.
    Kuhajda FP; Abeloff MD; Eggleston JC
    Hum Pathol; 1985 Mar; 16(3):228-35. PubMed ID: 2579017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Mansell J; Monypenny IJ; Skene AI; Abram P; Carpenter R; Gattuso JM; Wilson CR; Angerson WJ; Doughty JC
    Breast Cancer Res Treat; 2009 Sep; 117(1):91-8. PubMed ID: 19112615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
    Shao ZM; Wu J; Shen ZZ; Nguyen M
    Clin Cancer Res; 2001 Aug; 7(8):2222-7. PubMed ID: 11489795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers.
    Masood S
    Surg Oncol Clin N Am; 1995 Oct; 4(4):601-32. PubMed ID: 8535901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node-negative breast carcinoma.
    Leong C; Boyages J; Jayasinghe UW; Bilous M; Ung O; Chua B; Salisbury E; Wong AY
    Cancer; 2004 May; 100(9):1823-32. PubMed ID: 15112262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].
    Fodor J
    Magy Onkol; 2007; 51(2):127-31. PubMed ID: 17660868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence.
    Shen J; Hunt KK; Mirza NQ; Buchholz TA; Babiera GV; Kuerer HM; Bedrosian I; Ross MI; Ames FC; Feig BW; Singletary SE; Cristofanilli M; Meric-Bernstam F
    Cancer; 2005 Aug; 104(3):479-90. PubMed ID: 15968686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.